PHILADELPHIA, March 23, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the “Company”), announced today the publication of an editorial entitled “TLR3 agonists as immunotherapeutic agents,” published in the March 15, 2010 edition of Immunotherapy (2010) 2(2), 137-140, co-authored by Jonathan S. Berek, MD, Chairman, Stanford University School of Medicine Department of Obstetrics and Gynecology, and Christopher F. Nicodemus, MD, Chairman and Chief Scientific Officer, Advanced Immune Therapeutics, Inc., and HEB Consultant. Drs. Berek and Nicodemus have collaborated for more than a decade seeking to identify novel strategies to mobilize immunity to treat cancer and have conducted and published numerous preclinical and clinical studies, most notably in the field of ovarian cancer. Their long standing research interests form the basis for an active collaboration with the Company to evaluate the potential for Ampligen® (rintatolimod, Poly I : Poly C12U) and TLR3 agonists as cancer immunotherapeutics.
